[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.128.52. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Comment & Response
July 2014

Indications and Limitations of Vismodegib for Basal Cell Carcinoma

Author Affiliations
  • 1Orbital Oncology and Ophthalmic Plastic Surgery Program, Department of Plastic Surgery, The University of Texas MD Anderson Cancer Center, Houston
JAMA Ophthalmol. 2014;132(7):905-906. doi:10.1001/jamaophthalmol.2014.1787

To the Editor Gill et al1 reported the use of vismodegib in 7 patients with recurrent periocular and orbital basal cell carcinoma (BCC). Similar to the landmark 2012 study by Sekulic et al2 of 33 patients with metastatic and locally advanced BCC treated with vismodegib, the authors found an overall response rate of 57.1% (4 of 7 patients) with a median follow-up of 8 months compared with 43% in the phase 2 study. The authors state that this was the first series of periocular and orbital BCC cases treated with vismodegib; however, previous reviews have been published on the use of vismodegib for periocular lesions,3 and the 2012 study by Sekulic and colleagues included periocular lesions.

First Page Preview View Large
First page PDF preview
First page PDF preview
×